Physician profile
Jayesh Patel
NPI 1932203171
$20,725.94
in general payments reported to CMS, 2019-2025
60 companies · $3,743 in 2025
The $3,743 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,835 · 2020: $1,935 · 2021: $2,551 · 2022: $3,194 · 2023: $4,005 · 2024: $3,463 · 2025: $3,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,054.29 |
| Education | $157.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,383.07 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,589.48 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,787.39 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,440.38 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $1,093.35 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $1,018.96 | 2019-2025 | |
| Amgen INC. | $810.81 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $726.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $644.18 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Astellas Pharma US INC | $526.41 | 2020-2025 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $421.41 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.34 | 2020-2025 | Xifaxan |
| Intuity Medical INC | $324.40 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Merck Sharp & Dohme LLC | $292.20 | 2019-2023 | Verquvo, Segluromet, Steglatro |
| Regeneron Healthcare Solutions, INC. | $254.74 | 2021-2025 | Dupixent |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.